Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Comment on 'High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer'.

Ho-Yen C, Bowen RL, Kermorgant S, Jones JL.

Br J Cancer. 2013 May 28;108(10):2195-6. doi: 10.1038/bjc.2013.249. Epub 2013 May 14. No abstract available.

2.

High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer.

Zagouri F, Bago-Horvath Z, Rössler F, Brandstetter A, Bartsch R, Papadimitriou CA, Dimitrakakis C, Tsigginou A, Papaspyrou I, Giannos A, Dimopoulos MA, Filipits M.

Br J Cancer. 2013 Mar 19;108(5):1100-5. doi: 10.1038/bjc.2013.31. Epub 2013 Feb 19.

3.

Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer.

Polioudaki H, Agelaki S, Chiotaki R, Politaki E, Mavroudis D, Matikas A, Georgoulias V, Theodoropoulos PA.

BMC Cancer. 2015 May 13;15:399. doi: 10.1186/s12885-015-1386-7.

4.

The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features.

Aloia A, Petrova E, Tomiuk S, Bissels U, Déas O, Saini M, Zickgraf FM, Wagner S, Spaich S, Sütterlin M, Schneeweiss A, Reitberger M, Rüberg S, Gerstmayer B, Agorku D, Knöbel S, Terranegra A, Falleni M, Soldati L, Sprick MR, Trumpp A, Judde JG, Bosio A, Cairo S, Hardt O.

Breast Cancer Res. 2015 Nov 25;17(1):146. doi: 10.1186/s13058-015-0652-6.

5.

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.

Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM.

Breast Cancer Res. 2010;12(5):R68. doi: 10.1186/bcr2635. Epub 2010 Sep 2.

6.

Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.

Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, Marcom PK, George DJ, Garcia-Blanco MA.

Mol Cancer Res. 2011 Aug;9(8):997-1007. doi: 10.1158/1541-7786.MCR-10-0490. Epub 2011 Jun 10.

7.

Hyaluronan synthase 2 is an adverse prognostic marker in androgen receptor-negative breast cancer.

Zhang H, Tsang JY, Ni YB, Chan SK, Chan KF, Cheung SY, Tse GM.

J Clin Pathol. 2016 Dec;69(12):1055-1062. doi: 10.1136/jclinpath-2016-203617. Epub 2016 May 11.

PMID:
27169756
8.

Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients.

Krawczyk N, Meier-Stiegen F, Banys M, Neubauer H, Ruckhaeberle E, Fehm T.

Biomed Res Int. 2014;2014:415721. doi: 10.1155/2014/415721. Epub 2014 May 8. Review.

9.

Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.

Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, Agelaki S.

Breast Cancer Res. 2011 Jun 10;13(3):R59. doi: 10.1186/bcr2896.

10.

p66ShcA promotes breast cancer plasticity by inducing an epithelial-to-mesenchymal transition.

Hudson J, Ha JR, Sabourin V, Ahn R, La Selva R, Livingstone J, Podmore L, Knight J, Forrest L, Beauchemin N, Hallett M, Park M, Ursini-Siegel J.

Mol Cell Biol. 2014 Oct 1;34(19):3689-701. doi: 10.1128/MCB.00341-14. Epub 2014 Jul 28.

11.

Regulatory Proteins of Epithelial-Mesenchymal Transition and Some Components of VEGF Signaling Pathway in Breast Cancer.

Scherbakov AM, Gershtein ES, Korotkova EA, Ovchinnikova LK, Ovsii OG, Ermilova VD, Gens GP, Kushlinskii NE.

Bull Exp Biol Med. 2016 Apr;160(6):802-6. doi: 10.1007/s10517-016-3314-5. Epub 2016 May 11.

PMID:
27165081
12.

Role of epithelial-mesenchymal transition markers in triple-negative breast cancer.

Cheung SY, Boey YJ, Koh VC, Thike AA, Lim JC, Iqbal J, Tan PH.

Breast Cancer Res Treat. 2015 Aug;152(3):489-98. doi: 10.1007/s10549-015-3485-1. Epub 2015 Jun 30.

PMID:
26123543
13.

Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer.

Liu J, Chen X, Ward T, Mao Y, Bockhorn J, Liu X, Wang G, Pegram M, Shen K.

Int J Biochem Cell Biol. 2016 Feb;71:12-23. doi: 10.1016/j.biocel.2015.11.014. Epub 2015 Nov 28.

PMID:
26643609
14.

Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer.

Pomp V, Leo C, Mauracher A, Korol D, Guo W, Varga Z.

Breast Cancer Res Treat. 2015 Nov;154(1):45-55.

PMID:
26467042
15.

Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.

Jang MH, Kim HJ, Kim EJ, Chung YR, Park SY.

Hum Pathol. 2015 Sep;46(9):1267-74. doi: 10.1016/j.humpath.2015.05.010. Epub 2015 May 30.

PMID:
26170011
16.

Constitutive expression of γ-H2AX has prognostic relevance in triple negative breast cancer.

Nagelkerke A, van Kuijk SJ, Sweep FC, Nagtegaal ID, Hoogerbrugge N, Martens JW, Timmermans MA, van Laarhoven HW, Bussink J, Span PN.

Radiother Oncol. 2011 Oct;101(1):39-45. doi: 10.1016/j.radonc.2011.07.009. Epub 2011 Aug 15.

17.

Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer.

Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-MacGregor M, Tsavachidis S, Meric-Bernstam F, Do KA, Hortobagyi GN, Thompson PA, Mills GB, Bondy ML, Blumenschein GR Jr.

Cancer. 2013 Jan 1;119(1):7-15. doi: 10.1002/cncr.27608. Epub 2012 Jun 26.

18.

Prognostic value of tumor-associated macrophages according to histologic locations and hormone receptor status in breast cancer.

Gwak JM, Jang MH, Kim DI, Seo AN, Park SY.

PLoS One. 2015 Apr 17;10(4):e0125728. doi: 10.1371/journal.pone.0125728. eCollection 2015.

19.

Over-Expressed Twist Associates with Markers of Epithelial Mesenchymal Transition and Predicts Poor Prognosis in Breast Cancers via ERK and Akt Activation.

Zhang YQ, Wei XL, Liang YK, Chen WL, Zhang F, Bai JW, Qiu SQ, Du CW, Huang WH, Zhang GJ.

PLoS One. 2015 Aug 21;10(8):e0135851. doi: 10.1371/journal.pone.0135851. eCollection 2015.

20.

Intratumoral bidirectional transitions between epithelial and mesenchymal cells in triple-negative breast cancer.

Yamamoto M, Sakane K, Tominaga K, Gotoh N, Niwa T, Kikuchi Y, Tada K, Goshima N, Semba K, Inoue JI.

Cancer Sci. 2017 Jun;108(6):1210-1222. doi: 10.1111/cas.13246. Epub 2017 May 21.

Supplemental Content

Support Center